Get the Stockscreener App
3.22
0.00%
0.00
Indaptus Therapeutics Inc stock is traded at $3.22, with a volume of 4,938.
It is up +0.00% in the last 24 hours and down -1.53% over the past month.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
See More
Previous Close:
$3.22
Open:
$3.24
24h Volume:
4,938
Relative Volume:
0.01
Market Cap:
$3.57M
Revenue:
-
Net Income/Loss:
$-15.42M
P/E Ratio:
-1.75
EPS:
-1.84
Net Cash Flow:
$-13.41M
1W Performance:
-9.30%
1M Performance:
-1.53%
6M Performance:
+600.00%
1Y Performance:
+176.39%
1-Day Range:
$3.22
$3.33
1-Week Range:
$3.11
$3.64
52-Week Range:
$0.2701
$13.40
Indaptus Therapeutics Inc Stock (INDP) Company Profile
Name
Indaptus Therapeutics Inc
Sector
Industry
Phone
(646) 427-2727
Address
3 COLUMBUS CIRCLE, NEW YORK
Compare INDP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDP
Indaptus Therapeutics Inc
|
3.23 | 3.56M | 0 | -15.42M | -13.41M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.98 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.24 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.40 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.45 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
181.60 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Indaptus Therapeutics Inc Stock (INDP) Latest News
Why Indaptus Therapeutics Inc. stock could see breakout soonJuly 2025 Levels & Daily Oversold Bounce Ideas - newser.com
Is Indaptus Therapeutics Inc. stock ready for a breakoutAnalyst Upgrade & Community Verified Watchlist Alerts - newser.com
Key resistance and support levels for Indaptus Therapeutics Inc.Trade Volume Report & Daily Entry Point Alerts - newser.com
What momentum indicators show for Indaptus Therapeutics Inc. stockPortfolio Risk Summary & High Yield Equity Trading Tips - newser.com
Volume spikes in Indaptus Therapeutics Inc. stock – what they meanQuarterly Market Review & Comprehensive Market Scan Reports - newser.com
Volatility clustering patterns for Indaptus Therapeutics Inc.2025 Valuation Update & Safe Capital Growth Stock Tips - newser.com
Does Indaptus Therapeutics Inc. fit your quant trading modelInflation Watch & Weekly Stock Breakout Alerts - newser.com
Can Indaptus Therapeutics Inc. stock double in next 5 yearsQuarterly Earnings Report & High Conviction Buy Zone Alerts - newser.com
Visual trend scoring systems applied to Indaptus Therapeutics Inc.July 2025 Volume & Free Technical Confirmation Trade Alerts - newser.com
How Indaptus Therapeutics Inc. stock performs in interest rate cycles2025 Dividend Review & Smart Allocation Stock Tips - newser.com
How high can Indaptus Therapeutics Inc. stock go2025 Volume Leaders & Advanced Swing Trade Entry Alerts - newser.com
Why retail investors pile into Indaptus Therapeutics Inc. stockJuly 2025 Drop Watch & Consistent Growth Stock Picks - newser.com
Exit strategy if you’re trapped in Indaptus Therapeutics Inc.Weekly Market Summary & Safe Capital Allocation Plans - newser.com
How Indaptus Therapeutics Inc. stock performs in rising dollar environmentAnalyst Upgrade & AI Based Buy and Sell Signals - newser.com
Will earnings trigger a reversal in Indaptus Therapeutics Inc.Weekly Stock Recap & Growth Focused Entry Reports - newser.com
Building trade automation scripts for Indaptus Therapeutics Inc.Take Profit & Long-Term Capital Growth Strategies - newser.com
Backtesting results for Indaptus Therapeutics Inc. trading strategies2025 Fundamental Recap & High Accuracy Investment Signals - newser.com
What Wall Street predicts for Indaptus Therapeutics Inc. stock priceJuly 2025 Outlook & AI Based Buy/Sell Signal Reports - newser.com
Indaptus Therapeutics (INDP) Price Target Decreased by 86.15% to 25.50 - MSN
Why analysts upgrade Indaptus Therapeutics Inc. stockEarnings Recap Summary & AI Enhanced Trading Alerts - newser.com
Why Indaptus Therapeutics Inc. stock is a must watch in 2025July 2025 Volume & Daily Growth Stock Investment Tips - fcp.pa.gov.br
Indaptus Therapeutics Inc Stock (INDP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.68%
0.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):